Collectively, our findings reveal a previously unrecognized mechanism of ECH1‐Wnt5a/Ca2+ regulation in CAVD, implying that targeting ECH1 may be a potential therapeutic strategy to prevent CAVD development. Here, ECH1 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.